Pioneering Nitrase Medicines
Through Groundbreaking Biology

Nitrase Therapeutics is a leading biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, a new class of enzymes discovered in-house that offer the promise of a pipeline of therapies against a broad variety of diseases. Our breakthrough discovery of the enzymatic nature of protein nitration by nitrases, as well as our understanding of their exquisitely selective and specific mechanism of action, enables the identification of novel and differentiated small molecule drugs that target the core biologic processes of many diseases.

As pioneers in the field, we are in a unique position to discover and develop novel medicines for diseases in which nitrases and nitro-substrates play a role. We are initially focused on both Parkinson’s disease and cancer, but nitrases and their nitro-substrates are also implicated in other neurodegenerative diseases, fibrotic diseases, respiratory diseases, and autoimmune diseases. Our lead development candidate is a first-in-class antibody targeting extracellular nitrated alpha-synuclein (𝛂-synuclein) for the treatment of Parkinson’s disease (PD) and other synucleinopathies.

Nitrase Therapeutics (under the former name Nitrome Biosciences) has been widely recognized and has won multiple awards including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).